Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.85 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | PGD | P52209 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30003734 | 1.00 | PDE4A (0.85) | PDE4ALMNAUSP2SLCO1B1TSHR | |
| SCHEMBL16609882 | 1.00 | PDE4A (0.85) | PDE4ALMNAUSP2SLCO1B1TSHR | |
| SCHEMBL15457624 | 1.00 | PDE4A (0.85) | PDE4ALMNAUSP2SLCO1B1TSHR | |
| SCHEMBL192117 | 1.00 | PDE4A (0.85) | PDE4ALMNAUSP2SLCO1B1TSHR | |
| SCHEMBL13219455 | 1.00 | PDE4A (0.85) | PDE4ALMNAUSP2SLCO1B1TSHR | |
| SCHEMBL12395079 | 1.00 | PDE4A (0.85) | PDE4ALMNAUSP2SLCO1B1TSHR | |
| SCHEMBL15186907 | 1.00 | PDE4A (0.85) | PDE4ALMNAUSP2SLCO1B1TSHR | |
| SCHEMBL5238369 | 1.00 | PDE4A (0.85) | PDE4ALMNAUSP2SLCO1B1TSHR | |
| SCHEMBL16609879 | 1.00 | PDE4A (0.85) | PDE4ALMNAUSP2SLCO1B1TSHR | |
| SCHEMBL338307 | 1.00 | PDE4A (0.85) | PDE4ALMNAUSP2SLCO1B1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1893 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144729-A1 | A CLEANSING COMPOSITION | L'OREAL (FR) | 2026-05-28 | — | — | US | claimed |
| EP-3869192-B1 | METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE | HUMAN METABOLOMICS INST INC (CN) | 2026-05-13 | — | — | EP | claimed |
| EP-4731169-A1 | COMPOSITION WITH CHITOSAN AND A NATURAL RESIN | L'OREAL (FR) | 2026-04-29 | — | — | EP | claimed |
| EP-4731310-A1 | COMPOSITION WITH CHITOSAN AND A MODIFIED POLYSACCHARIDE | L'OREAL (FR) | 2026-04-29 | — | — | EP | claimed |
| EP-4731174-A1 | COSMETIC COMPOSITION BASED ON CHITOSAN AND AT LEAST ONE CRYSTALLIZABLE FATTY COMPOUND | L'OREAL (FR) | 2026-04-29 | — | — | EP | claimed |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| EP-3334274-B1 | USE OF COMPOSITIONS FOR PEST CONTROL | BIODEL AG INC (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260028524-A1 | BLEND OF PHOSPHONATE ACIDS FOR SCALE PREVENTION IN HIGH ALKALINITY AND HIGH CO2 ENVIRONMENTS | HALLIBURTON ENERGY SERVICES, INC (US) | 2026-01-29 | — | — | US | claimed |
| WO-2025263641-A1 | COMPOSITION COMPRISING GLYCOLIPID, CATIONIC POLYMER AND (POLY)HYDROXY ACID | L'OREAL (FR) | 2025-12-26 | — | — | WO | claimed |
| US-12502654-B2 | Hydrogenation catalyst and preparation method therefor and use thereof | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2025-12-23 | — | — | US | claimed |
| EP-4010301-A1 | A CARBONATED COMPOSITE | CRH Group Services Limited (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-3822247-B1 | PROCESSES FOR PREPARING ALDARIC, ALDONIC, AND URONIC ACIDS | ARCHER DANIELS MIDLAND CO (US) | 2022-06-08 | — | — | EP | claimed |
| EP-3997164-A1 | USE OF PHENOLICALLY SUBSTITUTED SUGAR DERIVATIVES AS STABILISERS, PLASTIC COMPOSITION, METHOD FOR STABILISING PLASTICS AND PHENOLICALLY SUBSTITUTED SUGAR DERIVATIVES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-05-18 | — | — | EP | claimed |
| US-20220146526-A1 | METHOD FOR EVALUATING SAMPLE, ANALYSIS METHOD, METHOD FOR DETECTING DEGRADED SAMPLE, MARKER FOR DETECTING DEGRADED BLOOD PLASMA SAMPLE, AND MARKER FOR DETECTING DEGRADED SERUM SAMPLE | SHIMADZU CORPORATION (JP) | 2022-05-12 | — | — | US | claimed |
| CN-114341246-A | Use of a phenol-substituted sugar derivative as a stabilizer, a plastic composition, a method of stabilizing a plastic material and a phenol-substituted sugar derivative | 弗劳恩霍夫应用研究促进协会 | 2022-04-12 | — | — | CN | claimed |
| US-20220026398-A1 | QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP | HUMAN METABOLOMICS INSTITUTE INC. (CN) | 2022-01-27 | — | — | US | claimed |
| US-20210388363-A1 | MODULATORS AND MODULATION OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS RNA | MONASH UNIVERSITY (AU) | 2021-12-16 | — | — | US | claimed |
| US-20180112213-A1 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | EDITAS MEDICINE, INC. (US) | 2018-04-26 | — | — | US | claimed |
| EP-3274454-A1 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | Editas Medicine, Inc. (US) | 2018-01-31 | — | — | EP | claimed |
| WO-2016154596-A1 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | EDITAS MEDICINE, INC. (US) | 2016-09-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028524-A1 | BLEND OF PHOSPHONATE ACIDS FOR SCALE PREVENTION IN HIGH ALKALINITY AND HIGH CO2 ENVIRONMENTS | PHOSPHO1, WEE1, PEBP1 | PDE4A 2939/4885LMNA 1990/4885USP2 4231/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | PDE4A 2030/4885LMNA 1592/4885USP2 1729/4885 |
| US-20180112213-A1 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | APOBEC3C, APOBEC3G, APOBEC3A | PDE4A 4371/4885LMNA 40/4885USP2 2136/4885 |
| US-20260144729-A1 | A CLEANSING COMPOSITION | SMURF1, CUTA, S100B | PDE4A 3903/4885LMNA 2006/4885USP2 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.